<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130324</url>
  </required_header>
  <id_info>
    <org_study_id>0113</org_study_id>
    <nct_id>NCT01130324</nct_id>
  </id_info>
  <brief_title>VIBATIV Pregnancy Registry</brief_title>
  <official_title>VIBATIV (Telavancin Hydrochloride) Pregnancy Exposure Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma Antibiotics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to evaluate the outcome of pregnancy in women exposed to
      VIBATIV at any time during pregnancy. There are no mandated physician visits for the
      registry.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>Outcomes of pregnancy in women exposed to VIBATIV at any time during pregnancy</measure>
    <time_frame>Once per trimester, 6-7 months gestation, and within 4 weeks after the estimated due date</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of fetal exposure to VIBATIV on pregnancy outcomes</measure>
    <time_frame>Within 4 weeks after the estimated due date and if a live infant birth is reported, at 3, 6, 9, and 12 months of age.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal/neonatal outcomes</measure>
    <time_frame>Within 4 weeks after the estimated due date and if a live infant birth is reported, at 3, 6, 9, and 12 months of age.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant development and milestones through 12 months of age</measure>
    <time_frame>Within 4 weeks after the estimated due date and if a live infant birth is reported, at 3, 6, 9, and 12 months of age.</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>VIBATIV treated pregnant women</arm_group_label>
    <description>Women treated with telavancin (any dose or duration) during pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIBATIV</intervention_name>
    <description>Observational</description>
    <arm_group_label>VIBATIV treated pregnant women</arm_group_label>
    <other_name>telavancin</other_name>
    <other_name>TD-6424</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women exposed to VIBATIV during pregnancy and where outcome of pregnancy is unknown at time
        of enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients who were exposed to VIBATIV at any time during pregnancy

          -  Outcome of pregnancy is unknown at the time of enrollment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bibiana Castaneda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma R &amp; D, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mia Elliott</last_name>
    <phone>(650) 808-6444</phone>
    <email>MElliott@theravance.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Theravance Biopharma R&amp;D, Inc. Medical Information</last_name>
    <phone>1-855-633-8479</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Theravance Biopharma R&amp;D, Inc.</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VIBATIV</keyword>
  <keyword>telavancin</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Registry</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telavancin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

